During 2018 Q4 the big money sentiment decreased to 1.23. That’s change of 0.21, from 2018Q3’s 1.44. 30 investors sold all, 67 reduced holdings as Myriad Genetics, Inc. ratio is negative. 90 increased positions while 29 funds took positions. Funds hold 74.41 million shares thus 2.06% more from 2018Q3’s 72.91 million shares.
Cibc World Mkts invested in 0% or 7,106 shs. Ingalls Snyder Ltd Llc owns 49,526 shs or 0.08% of their US capital. Thompson Siegel Walmsley Limited Liability Corp owns 328 shs. 12.20 million are owned by Blackrock. Acadian Asset Limited Liability Co holds 0.27% in Myriad Genetics, Inc. (NASDAQ:MYGN) or 1.86 million shs. Oregon Pub Employees Retirement Fund accumulated 0.02% or 826,518 shs. Texas Permanent School Fund invested in 0.03% or 48,923 shs. Mackay Shields Ltd Llc owns 0% invested in Myriad Genetics, Inc. (NASDAQ:MYGN) for 20,731 shs. Principal Fincl Group Inc Inc holds 644,908 shs. Prudential Financial Incorporated invested in 0.02% or 414,671 shs. Morgan Stanley has invested 0.01% in Myriad Genetics, Inc. (NASDAQ:MYGN). Numerixs Investment Technologies Inc owns 4,700 shs. Daiwa Securities Grp Inc stated it has 383 shs. Moreover, Point72 Asset Management L P has 0.13% invested in Myriad Genetics, Inc. (NASDAQ:MYGN) for 936,507 shs. Falcon Point Limited Liability Company invested in 71,927 shs.

Myriad Genetics, Inc. (NASDAQ:MYGN) Ratings Coverage

In total 8 analysts cover Myriad Genetics (NASDAQ:MYGN). “Buy” rating has 5, “Sell” are 1, while 2 are “Hold”. (NASDAQ:MYGN) has 63% bullish analysts. 10 are the (NASDAQ:MYGN)’s ratings reports on Mar 25, 2019 according to StockzIntelligence Inc. On Thursday, March 14 the stock of Myriad Genetics, Inc. (NASDAQ:MYGN) earned “Buy” rating by Piper Jaffray. On Friday, November 30 the company was upgraded by Goldman Sachs. In Wednesday, October 10 report PiperJaffray upgraded the stock to “Overweight” rating. On Monday, November 5 the rating was maintained by Deutsche Bank with “Hold”. On Wednesday, October 10 the stock has “Overweight” rating by Morgan Stanley. On Thursday, January 3 Barclays Capital maintained the shares of MYGN in report with “Underweight” rating. On Friday, January 4 the rating was upgraded by Cowen & Co to “Outperform”. In Tuesday, March 12 report Needham maintained the stock with “Buy” rating. Listed here are Myriad Genetics, Inc. (NASDAQ:MYGN) PTs and latest ratings.

14/03/2019 Broker: Piper Jaffray Rating: Buy New Target: $47 Maintain
12/03/2019 Broker: Needham Rating: Buy New Target: $41 Maintain
06/03/2019 Broker: BidaskScore Rating: Hold Downgrade
04/01/2019 Broker: Cowen & Co Old Rating: Market Perform New Rating: Outperform Upgrade
03/01/2019 Broker: Barclays Capital Old Rating: Underweight New Rating: Underweight Old Target: $23 New Target: $21 Maintain
03/01/2019 Broker: Needham Rating: Strong Buy New Target: $36 Initiates Coverage On
30/11/2018 Broker: Goldman Sachs Old Rating: Sell New Rating: Neutral Old Target: $28 New Target: $32 Upgrade
05/11/2018 Broker: Deutsche Bank Old Rating: Hold New Rating: Hold Old Target: $37 New Target: $43 Maintain
10/10/2018 Broker: Morgan Stanley Old Rating: Overweight New Rating: Overweight Old Target: $51 New Target: $54 Maintain
10/10/2018 Broker: PiperJaffray Old Rating: Neutral New Rating: Overweight Old Target: $38 New Target: $53 Upgrade

MYGN is reaching $33.1 during the last trading session, after decreased 1.25%.Currently Myriad Genetics, Inc. is downtrending after 4.31% change in last March 25, 2018. MYGN has also 901,726 shares volume. The stock underperformed the S&P500 by 8.68%.

Myriad Genetics, Inc., a molecular diagnostic company, focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide.The firm is valued at $2.43 billion. The firm offers molecular diagnostic tests, including myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; BART, a DNA sequencing test for hereditary breast and ovarian cancer; BRACAnalysis CDx, a DNA sequencing test for use as a companion diagnostic with the platinum based chemotherapy agents and poly ADP ribose inhibitor Lynparza; and Tumor BRACAnalysis CDx, a DNA sequencing test that is designed to be utilized to predict response to DNA damaging agents.108.17 is the P/E ratio. It also provides COLARIS, a DNA sequencing test for colorectal and uterine cancer; COLARIS AP, a DNA sequencing test for colorectal cancer; Vectra DA, a protein quantification test for assessing the disease activity of rheumatoid arthritis; Prolaris, a RNA expression test for assessing the aggressiveness of prostate cancer; and EndoPredict, a RNA expression test for assessing the aggressiveness of breast cancer.

For more Myriad Genetics, Inc. (NASDAQ:MYGN) news brought out recently go to: Nasdaq.com, Nasdaq.com, Seekingalpha.com, Nasdaq.com or Globenewswire.com. The titles are as follows: “Earnings Reaction History: Myriad Genetics Inc., 66.7% Follow-Through Indicator, 11.3% Sensitive – Nasdaq” brought out on February 05, 2019, “Myriad’s myPath Melanoma Test Awarded Medicare Coverage – Nasdaq” on March 18, 2019, “Myriad Genetics updates revenue guidance – Seeking Alpha” with a publish date: November 07, 2018, “Here’s Why Myriad Genetics Lost 28.4% in November – Nasdaq” and the last “Report: Exploring Fundamental Drivers Behind ArcelorMittal, Cohen & Steers, Myriad Genetics, Lexington Realty Trust, NorthWestern, and Chesapeake Utilities — New Horizons, Emerging Trends, and Upcoming Developments – GlobeNewswire” with publication date: March 07, 2019.